Amarin Zelapar "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amarin's orally disintegrating formulation of selegiline, Zelapar, is deemed "approvable" Feb. 7. The NDA, for use of Zelapar as an adjunct to levodopa for symptoms of Parkinson's disease, was accepted for filing by FDA April 6, 200
Amarin's orally disintegrating formulation of selegiline, Zelapar , is deemed "approvable" Feb. 7. The NDA, for use of Zelapar as an adjunct to levodopa for symptoms of Parkinson's disease, was accepted for filing by FDA April 6, 2002 |